Sanofi (NYSE:SNY)’s share price was down 1% during mid-day trading on Tuesday . The company traded as low as $38.89 and last traded at $39.02, with a volume of 4,990,551 shares changing hands. The stock had previously closed at $39.40.

A number of equities analysts recently issued reports on SNY shares. Zacks Investment Research cut Sanofi from a “hold” rating to a “sell” rating in a report on Wednesday, August 3rd. Citigroup Inc. reiterated a “neutral” rating on shares of Sanofi in a report on Wednesday, April 27th. TheStreet upgraded Sanofi from a “hold” rating to a “buy” rating in a report on Wednesday, July 27th. JPMorgan Chase & Co. reiterated a “sell” rating on shares of Sanofi in a report on Monday, April 25th. Finally, Berenberg Bank reiterated a “hold” rating and issued a $93.00 target price on shares of Sanofi in a report on Monday, August 15th. Four investment analysts have rated the stock with a sell rating, six have assigned a hold rating and five have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average target price of $60.50.

The firm has a market cap of $100.52 billion and a P/E ratio of 21.75. The stock’s 50-day moving average is $41.08 and its 200 day moving average is $40.69.

A number of hedge funds have made changes to their positions in the company. Rhumbline Advisers increased its stake in shares of Sanofi by 7.3% in the fourth quarter. Rhumbline Advisers now owns 26,510 shares of the company’s stock worth $1,131,000 after buying an additional 1,800 shares during the period. Stephens Inc. AR increased its stake in shares of Sanofi by 4.5% in the fourth quarter. Stephens Inc. AR now owns 56,811 shares of the company’s stock worth $2,423,000 after buying an additional 2,424 shares during the period. Finally, BlackRock Advisors LLC increased its stake in shares of Sanofi by 115.1% in the fourth quarter. BlackRock Advisors LLC now owns 695,109 shares of the company’s stock worth $29,646,000 after buying an additional 372,000 shares during the period.

Sanofi SA is a healthcare company focused on patient needs and engaged in the research, development, manufacture and marketing of healthcare products. The Company is organized around three principal activities: Pharmaceuticals, Human Vaccines via Sanofi Pasteur, and Animal Health via Merial. The Company invests in emerging markets, diabetes solutions, vaccines, consumer health care, animal health, genzyme and other products.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.